株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界のスマートピル技術市場:成長、動向、予測

Global Smart Pills Technology Market - Segmented by Technology, Disease Indication, and Geography - Growth, Trends, and Forecast (2018 - 2023)

発行 Mordor Intelligence LLP 商品コード 390697
出版日 ページ情報 英文 105 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=113.01円で換算しております。
Back to Top
世界のスマートピル技術市場:成長、動向、予測 Global Smart Pills Technology Market - Segmented by Technology, Disease Indication, and Geography - Growth, Trends, and Forecast (2018 - 2023)
出版日: 2018年04月01日 ページ情報: 英文 105 Pages
概要

スマートピル技術は、処方薬、ドラッグデリバリーシステム、患者のモニタリングなどに応用されているほか、大腸癌、便秘、胃不全麻痺などの消化器系疾患の診断に革命をもたらしています。

当レポートでは、世界のスマートピル技術市場について調査し、市場の概要、セグメント・地域別の市場動向、市場規模の推移と予測、市場成長・阻害要因の分析、市場シェア、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 市場の定義
  • 基本単位
  • 基本通貨
  • 調査対象期間と見通し
  • 一般調査の前提条件

第2章 調査方法

  • イントロダクション
  • 分析方法
  • 計量予測モデル
  • 調査の前提条件

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場概要と産業動向

  • 市場概況
  • スマートピル技術の応用
  • 技術概要
  • 新たな開発動向
  • 産業バリューチェーン分析
  • 製品ライフサイクル分析
  • 製品ベンチマーキング
  • 投資分析
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第6章 市場のダイナミクス

  • 市場の成長要因
    • 低侵襲性デバイスの人気
    • 消化器系疾患の有病率の上昇
    • 米国および日本の市場に有利な償還制度
    • 高齢者人口
    • 技術進歩
    • 身体状態の追跡と潜在的な病気の兆候の察知
  • 市場の阻害要因
    • 技術進歩によるコスト上昇
    • 倫理的な制約

第7章 世界のスマートピル技術市場:セグメンテーション

  • イントロダクション
  • 患者モニタリングデバイス
    • イントロダクション
    • 技術概要と市場動向
    • 市場規模と予測
  • ドラッグデリバリーシステム
    • イントロダクション
    • 技術概要と市場動向
    • 市場規模と予測
  • カプセル内視鏡
    • イントロダクション
    • 技術概要と市場動向
    • 市場規模と予測
  • スマートピル診断
    • イントロダクション
    • 技術概要と市場動向
    • 市場規模と予測

第8章 世界のスマートピル技術市場:地域別

  • 北米
    • イントロダクション
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • イントロダクション
    • ドイツ
    • 英国
    • フランス
    • スカンジナビア諸国
    • ベネルクス諸国
    • その他
  • アジア太平洋
    • イントロダクション
    • 中国
    • 日本
    • インド
    • オーストラリア・ニュージーランド
    • その他
  • 中東・北アフリカ
    • イントロダクション
    • 湾岸協力会議(GCC)
    • イスラエル
    • その他
  • 南米
    • イントロダクション
    • ブラジル
    • アルゼンチン
    • その他

第9章 競合情勢

  • M&A分析
  • 新製品の発売
  • 合意、コラボレーション、パートナーシップ

第10章 主要ベンダー分析

  • Novartis AG
  • Philips Healthcare
  • Medtronic
  • オリンパスメディカルテクノロジー
  • GE Healthcare
  • Given Imaging
  • Proteus
  • Boston Scientific Corporation
  • Smart Pill Inc.
  • Medimetrics

第11章 アナリストによる投資機会の見通し

第12章 市場の将来展望

目次
Product Code: 56721

The global smart pills technology market is expected to register a CAGR of 16% during the forecast period of 2018-2023. The smart pill is a wireless capsule that can be swallowed, and with the help of a receiver (worn by patients) and software that analyzes the pictures captured by the smart pill, the physician is effectively able to examine the gastrointestinal tract. Gastrointestinal disorders have become very common, but recently, there has been increasing incidence of colorectal cancer, inflammatory bowel disease, and Crohn's disease as well.

Increasing Preference for Minimally Invasive Device

Endoscopy surgeries, being minimally invasive, have become more popular in recent times. Latest studies show that there is an increasing demand for single incision or small incision type of surgery as an alternative to traditional surgeries. As aging patients are susceptible to complications, the usage of minimally invasive procedures is of utmost importance and the need of the hour. There are unexplained situations of bleeding, iron deficiency, abdominal pain, search for polyps, ulcers, and tumors of the small intestine, and inflammatory bowel disease, such as Crohn's disease, where capsule endoscopy diagnoses fare better than traditional endoscopy. Also, as capsule endoscopy is less invasive or non-invasive, as compared to traditional endoscopy, patients are increasingly preferring the usage of capsule endoscopy as it does not require any recovery time, which is driving the smart pill market.

The other factors, such as the increasing incidence of gastrointestinal disorders, technological advancements, and ability to track bodily functions and forewarn potential illness are driving the smart pills technology market.

Potential Health Risks of Smart Pills

There are certain risks associated with smart pills that might restrain their use. A smart pill usually leaves the body within two weeks. Sometimes, the pill might get lodged in the digestive tract rather than exiting the body via normal bowel movements. The risk might be higher in people with a tumor, Crohn's disease, or some surgery within that area that lead to narrowing of the digestive tract. CT scan is usually performed in people with high-risk to assess the narrowing of the tract. However, the pill might still be lodged even if the results are negative for the CT scan, which might lead to bowel obstruction and can be removed either by surgery or traditional endoscopy. Smart pills might lead to skin irritation, which results in mild redness and need to be treated topically. It may also lead to capsule aspiration, which involves the capsule going down the wrong pipe and entering the airway instead of the esophagus. This might result in choking and death if immediate bronchoscopic extraction is not performed. Patients with comorbidities related to brain injury or chronic obstructive pulmonary disease may be at a higher risk. So, the health risks associated with the use of smart pills are hindering the smart pills technology market. The other factors, such as increasing cost with technological advancement and ethical constraints are also hindering the market.

United States Leads the Market in North America

In 2017, the United States smart pills technology market held the largest market share in North America due to the presence of high-quality healthcare systems and modern medical technology in the country. Additionally, the growing healthcare policies from the government is likely to contribute towards the growth of the smart pills technology market.

Key Developments in the Market

September 2017: Scientists developed a miniature medical chip called as ATOMS, which can be used in ingestible smart pills to diagnose and treat diseases within the body.

November 2017: The FDA approved the first digital pill called Abilify MyCite.

Major Players: NOVARTIS AG, PROTEUS PHARMACEUTICALS, PHILLIPS, MICROCHIPS, VITALITY, PIXIE SCIENTIFIC, OLYMPUS MEDICAL TECHNOLOGY, GE HEALTHCARE, BOSTON SCIENTIFIC CORPORATION, and GIVEN IMAGING LTD, among others.

Reasons to Purchase the Report

Follow the current and future global smart pills technology market in the developed and emerging markets.

Examining the various perspectives of the market with the help of Porter's Five Forces Analysis.

Identify the segment that is expected to dominate the market.

Identify the regions that are expected to witness the fastest growth during the forecast period.

Identify the latest developments, market shares, and strategies employed by the major market players.

3-month analyst support along with the Market Estimate sheet (in Excel).

Customization of the Report

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threat of New Entrants
    • 5.2.4 Threat of Substitute Products and Services
    • 5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

  • 6.1 Drivers
    • 6.1.1 Increasing Preference for Minimally Invasive Device
    • 6.1.2 Increasing Incidence of Gastrointestinal Disorders
    • 6.1.3 Technological Advancements
    • 6.1.4 Ability to Track Bodily Functions and Forewarn Potential Illness
  • 6.2 Restraints
    • 6.2.1 Increasing Cost with Technological Advancement
    • 6.2.2 Ethical Constraints
    • 6.2.3 Potential Health Risks
  • 6.3 Opportunities
  • 6.4 Key Challenges

7. Market Segmentation

  • 7.1 By Technology
    • 7.1.1 Capsule Endoscopy
      • 7.1.1.1 Small Bowel Video Capsule Endoscopy
      • 7.1.1.2 Colon Capsule Endoscopy
    • 7.1.2 Patient Monitoring
    • 7.1.3 Drug Delivery
  • 7.2 By Disease Indication
    • 7.2.1 Occult GI Bleeding
    • 7.2.2 Crohn's Disease
    • 7.2.3 Small Bowel Tumors
    • 7.2.4 Celiac Disease
    • 7.2.5 Inherited Polyposis Syndromes
    • 7.2.6 Others
  • 7.3 By Geography
    • 7.3.1 North America
      • 7.3.1.1 United States
      • 7.3.1.2 Canada
      • 7.3.1.3 Mexico
    • 7.3.2 Europe
      • 7.3.2.1 France
      • 7.3.2.2 Germany
      • 7.3.2.3 United Kingdom
      • 7.3.2.4 Italy
      • 7.3.2.5 Spain
      • 7.3.2.6 Rest of Europe
    • 7.3.3 Asia-Pacific
      • 7.3.3.1 China
      • 7.3.3.2 Japan
      • 7.3.3.3 India
      • 7.3.3.4 Australia & New Zealand
      • 7.3.3.5 South Korea
      • 7.3.3.6 Rest of Asia-Pacific
    • 7.3.4 Middle East & Africa
      • 7.3.4.1 GCC
      • 7.3.4.2 South Africa
      • 7.3.4.3 Rest of the Middle East & Africa
    • 7.3.5 South America
      • 7.3.5.1 Brazil
      • 7.3.5.2 Argentina
      • 7.3.5.3 Rest of South America

8. Competitive Landscape

  • 8.1 Mergers & Acquisition Analysis
  • 8.2 Agreements, Collaborations, and Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.1 Boston Scientific Corporation
  • 9.2 GE Healthcare
  • 9.3 Given Imaging Ltd
  • 9.4 Microchips
  • 9.5 Novartis AG
  • 9.6 Olympus Medical Technology
  • 9.7 Phillips
  • 9.8 Pixie Scientific
  • 9.9 Proteus Pharmaceuticals
  • 9.10 Vitality

List not Exhaustive

10. Future of the Market

11. Disclaimer

Back to Top